Work Files Saved Searches
   My Account                                                  Search:   Quick/Number   Boolean   Advanced   Derwent    Help   


 The Delphion Integrated View

  Buy Now:   Buy PDF- 12pp  PDF  |   File History  |   Other choices   
  Tools:  Citation Link  |  Add to Work File:    
  View:  Expand Details   |  INPADOC   |  Jump to: 
  Go to:  Derwent  
 Email this to a friend  Email this to a friend 
       
Title: US5474547: Implanting devices for the focal release of neuroinhibitory compounds
[ Derwent Title ]


Country: US United States of America

View Images High
Resolution

 Low
 Resolution

 
12 pages

 
Inventor: Aebischer, Patrick; Barrington, RI
Tresco, Patrick A.; Wakefield, RI

Assignee: Brown University Research Foundation, Providence, RI
other patents from BROWN UNIVERSITY RESEARCH FOUNDATION (78215) (approx. 140)
 News, Profiles, Stocks and More about this company

Published / Filed: 1995-12-12 / 1993-12-16

Application Number: US1993000168858

IPC Code: Advanced: A61F 2/02; A61K 9/00; A61K 9/22; A61K 31/195; A61M 31/00;
Core: A61K 31/185; more...
IPC-7: A61K 9/22;

ECLA Code: A61F2/02B; A61K9/00M22; A61K31/195; A61M31/00D;

U.S. Class: Current: 604/891.1; 128/898; 128/899; 424/424;
Original: 604/891.1; 128/898; 128/899; 424/424;

Field of Search: 604/049,890.1,891.1,27,28,93,56,43,116 623/011,12 424/422-424 128/897-899 435/041,180,182

Priority Number:
1993-12-16  US1993000168858
1992-07-13  US1992000912463
1989-06-21  US1989000369296

Abstract: Methods are disclosed for the alleviation of movement disorders via the implantation of static devices which focally release neuroinhibitory compounds to preselected brain areas. Pathological conditions to be treated by these methods include parkinsonian movement disorders, Huntington's chorea, and epileptiform seizure activity. In the treatment of parkinsonism, target areas implantation include the subthalamic nucleus, the globus pallidus internus, and the substantia nigra pars reticulata. In the treatment of epilepsy, implants may be placed in an epileptogenic focus area of neural over-activity. The devices may be polymeric implants that release neuroinhibitory compounds such as GABA, GABA agonists, GABA potentiators, action potential blockers and voltage dependent calcium channel blockers, and glutamate antagonists. Alternatively, the devices may contain living cells which secrete neuroinhibitory compounds.

Attorney, Agent or Firm: Flehr, Hohbach, Test, Albritton & Herbert ;

Primary / Asst. Examiners: Rosenbaum, C. Fred; Alexander, V.

INPADOC Legal Status: Show legal status actions          Buy Now: Family Legal Status Report

       
Related Applications:
Application Number Filed Patent Pub. Date  Title
US1992000912463 1992-07-13       
US1989000369296 1989-06-21       


       
Parent Case:

CROSS-REFERENCE TO RELATED APPLICATION
    This application is a divisional of U.S. Ser. No. 07/912,463 filed Jul. 13, 1992, which is a continuation-in-part of U.S. Ser. No. 07/369,296, filed Jun. 21, 1989, now abandoned. U.S. Ser. No. 07/841,875 filed Feb. 26, 1992, now U.S. Pat. No. 5,156,844, is a continuation of Ser. No. 07/369,296, which is a continuation-in-part of U.S. Ser. No. 07/121,626, filed Nov. 17, 1987, now U.S. Pat. No. 4,892,538.

Designated Country: BE CH DK FR GB GR IE IT LI LU MC NL PT SE  KR 

Family: Show 158 known family members

First Claim:
Show all 9 claims
What is claimed is:     1. A method for alleviating parkinsonian movement disorders in an individual having the same, comprising
  • implanting a static device adjacent a brain area within the basal ganglia of said individual, said brain area selected from the group consisting of the subthalamic nucleus, globus pallidus internus, and substantia nigra pars reticulata,
  • said device focally releasing at least one compound which acts to inhibit over-activity in at least one neuron within said brain area,
  • said compound being selected from the group consisting of GABA, GABA agonists, GABA potentiators, action potential blockers, voltage dependent calcium channel blockers, glutamate antagonists, phenytoin, carbamezepine, valproate, barbiturates, benzodiazapines, ethosuximide, tetrodotoxin, saxitoxin, and conotoxins,
  • said inhibition effecting the disruption of neural over-activity within said basal ganglia,
  • said disruption effecting the alleviation of said parkinsonian movement disorders.


Background / Summary: Show background / summary

Drawing Descriptions: Show drawing descriptions

Description: Show description

Forward References: Show 51 U.S. patent(s) that reference this one

       
U.S. References: Go to Result Set: All U.S. references   |  Forward references (51)   |   Backward references (7)   |   Citation Link

Buy
PDF
Patent  Pub.Date  Inventor Assignee   Title
Buy PDF- 5pp US4346112  1982-08 Henkel et al.  University Patents Inc. Composition and method for treating patients having Parkinson's Disease
Buy PDF- 5pp US4353888  1982-10 Sefton   Encapsulation of live animal cells
Buy PDF- 7pp US4892538  1990-01 Aebischer et al.  Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
Buy PDF- 10pp US5017375  1991-05 Appel et al.  Baylor College of Medicine Method to prepare a neurotrophic composition
Buy PDF- 14pp US5156844  1992-10 Aebischer et al.  Brown University Research Foundation Neurological therapy system
Buy PDF- 10pp US5158881  1992-10 Aebischer et al.  Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
Buy PDF- 13pp US5182111  1993-01 Aebischer et al.  Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
       
Foreign References: None

Other Abstract Info: CHEMABS 112(06)042603K DERABS C89-178223 DERABS C91-022071 DERABS C94-034784

Inquire Regarding Licensing

Powered by Verity


Plaques from Patent Awards      Gallery of Obscure PatentsNominate this for the Gallery...

Thomson Reuters Copyright © 1997-2010 Thomson Reuters 
Subscriptions  |  Web Seminars  |  Privacy  |  Terms & Conditions  |  Site Map  |  Contact Us  |  Help